User login
Key clinical point: Patients with type 2 diabetes (T2D) who maintain glycosylated hemoglobin (HbA1c) levels of <7% vs. ≥7% during a 5-year post-period have a lower risk for diabetes-related complications.
Major finding: Maintaining an HbA1c level of <7% vs. ≥7% during the 5-year post-period was associated with a lower risk of developing cardiovascular disease (odds ratio [OR] 0.76; 95% CI 0.61-0.94), metabolic disease (OR 0.37; 95% CI 0.22-0.60), neuropathy (OR 0.62; 95% CI 0.45-0.84), nephropathy (OR 0.81; 95% CI 0.69-0.94), and peripheral vascular disease (OR 0.52; 95% CI 0.33-0.83).
Study details: Findings are from a retrospective study including 3067 adult patients with T2D and sustained glycemic control (HbA1c <7%; n = 2,119) or sustained suboptimal glycemic control (HbA1c ≥7%; n = 1,488).
Disclosures: This study was funded by Eli Lilly and Company. KS Boye, R Paczkowski, and VT Thieu reported being employees and shareholders of Eli Lilly and MJ Lage received personal compensation from Eli Lilly.
Source: Boye KS et al. The association between sustained HbA1c control and long-term complications among individuals with type 2 diabetes: A retrospective study. Adv Ther. 2022 (Mar 22). Doi: 10.1007/s12325-022-02106-4
Key clinical point: Patients with type 2 diabetes (T2D) who maintain glycosylated hemoglobin (HbA1c) levels of <7% vs. ≥7% during a 5-year post-period have a lower risk for diabetes-related complications.
Major finding: Maintaining an HbA1c level of <7% vs. ≥7% during the 5-year post-period was associated with a lower risk of developing cardiovascular disease (odds ratio [OR] 0.76; 95% CI 0.61-0.94), metabolic disease (OR 0.37; 95% CI 0.22-0.60), neuropathy (OR 0.62; 95% CI 0.45-0.84), nephropathy (OR 0.81; 95% CI 0.69-0.94), and peripheral vascular disease (OR 0.52; 95% CI 0.33-0.83).
Study details: Findings are from a retrospective study including 3067 adult patients with T2D and sustained glycemic control (HbA1c <7%; n = 2,119) or sustained suboptimal glycemic control (HbA1c ≥7%; n = 1,488).
Disclosures: This study was funded by Eli Lilly and Company. KS Boye, R Paczkowski, and VT Thieu reported being employees and shareholders of Eli Lilly and MJ Lage received personal compensation from Eli Lilly.
Source: Boye KS et al. The association between sustained HbA1c control and long-term complications among individuals with type 2 diabetes: A retrospective study. Adv Ther. 2022 (Mar 22). Doi: 10.1007/s12325-022-02106-4
Key clinical point: Patients with type 2 diabetes (T2D) who maintain glycosylated hemoglobin (HbA1c) levels of <7% vs. ≥7% during a 5-year post-period have a lower risk for diabetes-related complications.
Major finding: Maintaining an HbA1c level of <7% vs. ≥7% during the 5-year post-period was associated with a lower risk of developing cardiovascular disease (odds ratio [OR] 0.76; 95% CI 0.61-0.94), metabolic disease (OR 0.37; 95% CI 0.22-0.60), neuropathy (OR 0.62; 95% CI 0.45-0.84), nephropathy (OR 0.81; 95% CI 0.69-0.94), and peripheral vascular disease (OR 0.52; 95% CI 0.33-0.83).
Study details: Findings are from a retrospective study including 3067 adult patients with T2D and sustained glycemic control (HbA1c <7%; n = 2,119) or sustained suboptimal glycemic control (HbA1c ≥7%; n = 1,488).
Disclosures: This study was funded by Eli Lilly and Company. KS Boye, R Paczkowski, and VT Thieu reported being employees and shareholders of Eli Lilly and MJ Lage received personal compensation from Eli Lilly.
Source: Boye KS et al. The association between sustained HbA1c control and long-term complications among individuals with type 2 diabetes: A retrospective study. Adv Ther. 2022 (Mar 22). Doi: 10.1007/s12325-022-02106-4